Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.

Drug Resistance, Neoplasm Fusion Proteins, bcr-abl / genetics Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy Mutation Oncogenes Protein Kinase Inhibitors / pharmacology
Chronic myeloid leukemia blast phase personalized medicine risk stratification somatic mutations

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 5 5 2021
medline: 25 2 2023
entrez: 4 5 2021
Statut: ppublish

Résumé

The

Identifiants

DOI: 10.1080/10428194.2021.1894652 PMID: 33944660
pubmed: 33944660
doi: 10.1080/10428194.2021.1894652
doi:

Substances chimiques

Protein Kinase Inhibitors 0
Fusion Proteins, bcr-abl EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2064-2078

Auteurs

Shady Adnan-Awad (S)

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.

Matti Kankainen (M)

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.
iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.

Satu Mustjoki (S)

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.
iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
ORCID: 0000-0002-0816-8241

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Mutational landscape of chronic myeloid...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-bcr › Protéines de fusion bcr-abl › Mutational landscape of chronic myeloid...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Mutational landscape of chronic myeloid...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Leucémie myéloïde chronique BCR-ABL positive › Mutational landscape of chronic myeloid...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mutational landscape of chronic myeloid...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes tumoraux › Oncogènes › Mutational landscape of chronic myeloid...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Mutational landscape of chronic myeloid...